| P50 | author | Kashif Aziz Khan | Q58380487 |
| | Daniel Wendling | Q66753972 |
| | Wasim Abbas | Q96013741 |
| | Georges Herbein | Q47015111 |
| P2093 | author name string | Eric Toussirot | |
| | Georges Herbein | |
| | Lucile Baud | |
| | Ewa Bertolini | |
| | Marion Tissot | |
| | Alicia Jeudy | |
| P2860 | cites work | Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. | Q53389033 |
| | Histone deacetylase inhibitors impair antibacterial defenses of macrophages. | Q54352898 |
| | Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients | Q54806462 |
| | Bcl-3-Regulated Transcription from Major Immediate-Early Promoter of Human Cytomegalovirus in Monocyte-Derived Macrophages | Q60595400 |
| | Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis | Q61633704 |
| | Histone hyperacetylation is associated with amelioration of experimental colitis in mice | Q83059529 |
| | SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance | Q84531194 |
| | The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression | Q24548310 |
| | Histone deacetylase 3, a class I histone deacetylase, suppresses MAPK11-mediated activating transcription factor-2 activation and represses TNF gene expression | Q28281070 |
| | Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines | Q28568728 |
| | Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection | Q33476165 |
| | Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes | Q33782118 |
| | Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis | Q33828002 |
| | The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines | Q34015778 |
| | Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis | Q34152949 |
| | Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases? | Q34393807 |
| | The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo | Q34504770 |
| | Histone deacetylase inhibitors in clinical development | Q35609717 |
| | Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. | Q36052572 |
| | Epigenetics in inflammatory rheumatic diseases | Q36985127 |
| | Epigenetic modifications in rheumatoid arthritis | Q37306838 |
| | Targeting histone deacetylase activity in rheumatoid arthritis and asthma as prototypes of inflammatory disease: should we keep our HATs on? | Q37317209 |
| | HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis | Q37838731 |
| | Function of histone deacetylase inhibitors in inflammation. | Q37899219 |
| | Sirt1: def-eating senescence? | Q38043910 |
| | Histone deacetylase/acetylase activity in total synovial tissue derived from rheumatoid arthritis and osteoarthritis patients | Q40229057 |
| | Exogenous Nef protein activates NF-kappa B, AP-1, and c-Jun N-terminal kinase and stimulates HIV transcription in promonocytic cells. Role in AIDS pathogenesis | Q40691772 |
| | Similarities and differences between human and murine TNF promoters in their response to lipopolysaccharide | Q40960914 |
| | Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model | Q41183432 |
| | Histone deacetylase inhibitors: a new and promising drug class for the treatment of arthritis? | Q42182612 |
| | Histone deacetylase inhibitors: new treatment options for inflammatory joint disease? | Q42930146 |
| | Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. | Q43143715 |
| | Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue | Q43184367 |
| | Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection | Q44166565 |
| | Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model | Q46786924 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ankylosing spondylitis | Q52849 |
| | rheumatoid arthritis | Q187255 |
| | TNF | Q18032037 |
| P304 | page(s) | e70939 | |
| P577 | publication date | 2013-08-15 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Imbalance between HAT and HDAC activities in the PBMCs of patients with ankylosing spondylitis or rheumatoid arthritis and influence of HDAC inhibitors on TNF alpha production | |
| P478 | volume | 8 | |